TBT Pharma
- Michael Richman
Mike is the CEO of NextCure, an immunooncology immuno-oncology company he took from startup to IPO. Previously, Mr. Richman served as the President and CEO of Amplimmune, which was acquired by AstraZeneca for $500M in 2013.